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Abstract 
In the past ten years we have made exceptional progresses in the understanding of RCC 
biology, particularly by recognizing the crucial pathogenetic role of activation of the 
HIF/VEGF and mTOR pathways. This has resulted in the successful clinical develop-
ment of anti-angiogenic and mTOR-targeted drugs, which have profoundly impacted on 
the natural history of the disease and have improved the duration and quality of RCC 
patient lives. However, further improvements are still greatly needed: 1) even in patients 
who obtain striking clinical responses early in the course of treatment, disease will ulti-
mately escape control and progress to a treatment-resistant state, leading to therapeutic 
failure; 2) prolonged disease control usually requires ‘continuous’ treatment, even across 
different treatment lines, making the impact of chronic, low-grade, toxicities on quality of 
life greater and precluding, for most patients, the possibility of experiencing ‘drug-free 
holidays’; 3) although we  have successfully  identified classes  of drugs (or molecular 
mechanisms of action) that are effective in a substantial proportion of patients, we still 
fall short of molecular predictive factors that identify individual patients who will (or 
will not) benefit from a specific intervention and still proceed on a trial-and-error basis, 
far from a truly ‘personalized’ therapeutic approach; 4) finally (and perhaps most im-
portantly), even in the best case scenario, currently available treatments inevitably fail to 
definitively ‘cure’ metastatic RCC patients. In this review we briefly summarize recent 
developments in the understanding of the molecular pathogenesis of RCC, the devel-
opment of resistance/escape mechanisms, the rationale for sequencing agents with dif-
ferent mechanisms of action, and the importance of host-related factors. Unraveling the 
complex mechanisms by which RCC shapes host microenvironment and immune re-
sponse  and  therapeutic  treatments,  in  turn,  shape  both  cancer  cell  biology  and  tu-
mor-host interactions may hold the key to future advances in such a complex and chal-
lenging disease. 
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The molecular revolution in renal cell carci-
noma 
In recent years, we have witnessed a profound 
revolution in the way we approach and treat renal cell 
carcinoma (RCC). In a relatively short time (10 years, 
approximately),  we  have  gone  from  a  very  limited 
range  of  therapeutic  options  [essentially  limited  to 
interferon (IFN) and, for the few patients fit enough to 
receive it, high-dose interleukin-2 (IL-2) or, more re-
cently, allogeneic bone marrow transplant] to almost a 
plethora of effective agents (at least 6 drugs currently 
approved  for  the  treatment  of  advanced  RCC  and 
more to come shortly), that has led to define the un-
certainties in treatment choices as the ‘embarrassment 
of the riches’. Such a revolution stems from a much 
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improved  understanding  of  RCC  biology,  predomi-
nantly  at  the  cancer  cell  level,  that  has  led  to  the 
recognition of common molecular themes underlying 
RCC pathogenesis and to the identification of relevant 
therapeutic  targets,  such  as  the  activation  of 
pro-angiogenic  and  of  the  mammalian  target  of  ra-
pamycin  (mTOR)  pathways  (1).  Successful  pharma-
cological targeting of these pathways has dramatically 
improved the management of patients with metastatic 
RCC, who have now access to many different treat-
ment  choices  across  multiple  lines  of  treatment,  re-
sulting in a striking prolongation of disease control, in 
most cases compatible with an acceptable quality of 
life, as well as in a life expectancy that approaches 
three years from the diagnosis of metastatic disease in 
the majority of patients. As a consequence, RCC has 
gone from a ‘orphan’ disease to a paradigm for the 
successful  development  of  biology-driven  therapies 
and currently constitutes a unique case among solid 
tumors, as the management of metastatic disease is 
entirely based on different classes of molecularly tar-
geted  drugs.  Exciting  successes  notwithstanding, 
several issues remain to be addressed in the treatment 
of  advanced  RCC:  1)  even  in  patients  who  obtain 
striking  clinical  responses  early  in  the  course  of 
treatment, disease will ultimately escape control and 
progress  to  a  treatment-resistant  state,  leading  to 
therapeutic failure; 2) prolonged disease control usu-
ally requires ‘continuous’ treatment, even across dif-
ferent treatment lines, making the impact of chronic, 
low-grade,  toxicities  on  quality  of  life  greater  and 
precluding, for most patients, the possibility of expe-
riencing  ‘drug-free  holidays’;  3)  although  we  have 
successfully identified classes of drugs (or molecular 
mechanisms of action) that are effective in a substan-
tial proportion of patients, we still fall short of mo-
lecular predictive factors that identify individual pa-
tients who  will (or will  not) benefit from a specific 
intervention and still proceed on a trial-and-error ba-
sis,  far  from  a  truly  ‘personalized’  therapeutic  ap-
proach;  4)  finally  (and  perhaps  most  importantly), 
even  in  the  best  case  scenario,  currently  available 
treatments inevitably fail to definitively ‘cure’ meta-
static RCC patients. One of the possible avenues to 
address such issues, possibly leading to further im-
provements in the management of advanced RCC, is 
to better understand the interplay between cancer cell 
biology,  host  response,  and  treatment-induced 
changes. Indeed, the presence of RCC actually shapes 
host response (e.g. in terms of immune reaction and 
microenvironmental changes), which, in turn, influ-
ences tumor biology (e.g. in terms of pathway activa-
tion),  in  a  complex  interplay  that  is  just  starting  to 
emerge; in addition, targeted therapies modify both 
cancer biology and host response, thereby adding a 
further level of complexity that we are only beginning 
to appreciate. Unraveling such complex interactions 
may hold the key to future advances in the compre-
hension of RCC biology and in the treatment of pa-
tients with this disease. 
Lessons learned from hereditary syndromes 
and common molecular themes in RCC 
The term RCC encompasses a highly heteroge-
neous group of malignancies, from both a morpho-
logical and a molecular point of view, but emerging 
evidence indicates that common  molecular paths to 
renal carcinogenesis do exist and may justify, to some 
extent, shared approaches to the clinical treatment of 
different  RCC  subtypes  (2).  Although  most  of  RCC 
cases  occur  in  a  sporadic  form,  both  clear  cell  and 
non-clear cell RCC can occur in the context of inher-
ited cancer syndromes, whose molecular genetics has 
shed light on potentially common molecular patho-
genetic themes (3-4). This is probably best exemplified 
by  von  Hippel-Lindau  disease  (VHL)  and  tuberous 
sclerosis  (TS),  two  autosomal  dominant  inherited 
syndromes with variable penetrance that carry a high 
lifetime risk of developing clear cell RCC (5-6). The 
VHL  gene,  which  targets  hypoxia  inducible  factor 
(HIF)-1 for degradation by the proteasome, is mu-
tated or silenced in up to 75% of sporadic clear cell 
RCC, suggesting that genetic abnormalities involved 
in inherited RCC syndromes (and subsequent altera-
tions in downstream intracellular signaling cascades) 
may also play a central role in sporadic RCC. In tu-
mors  carrying  a  mutated  VHL,  increased  levels  of 
HIF-1 play a critical oncogenic role by stimulating 
the transcription of many crucial downstream effec-
tors,  including  vascular  endothelial  growth  factor 
(VEGF),  platelet-derived  growth  factor  (PDGF), 
c-Met, transforming growth factor (TGF)-, and the 
stromal-derived  factor  (SDF)-1/CXCR4  lig-
and/receptor pair, among others (7). Of note, signal-
ing pathways initiated by such effectors, VEGF and 
PDGF  in  particular,  are  the  therapeutic  targets  of 
monoclonal  antibodies  and  small-molecule  kinase 
inhibitors  (TKIs)  that  currently  constitute  the  main-
stay of clinical RCC treatment. TS, on the other hand, 
is an autosomal dominant disorder with 95% pene-
trance, caused by mutations in either the TSC1 (9q34) 
or the TSC2 (16p13.3) genes, encoding for the hamar-
tin and tuberin proteins, respectively. Hamartin and 
tuberin physically interact to form a complex, which, 
through the GAP activity of tuberin, inactivates the 
small  G-protein  Rheb,  thereby  relieving 
Rheb-mediated  mTOR  inhibition.  Therefore,  genetic 
inactivation  of  TSC1/2  results  in  the  uncontrolled  Journal of Cancer 2011, 2 
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activation  of  the  mTOR  pathway,  leading,  among 
other effects, to increased synthesis and accumulation 
of HIF, even in the absence of hypoxia, and transcrip-
tion of HIF-dependent genes (8-9). Indeed, activated 
mTOR, may exacerbate the loss of VHL function (or 
the  effects  of  hypoxia)  by  further  elevating  HIF-1 
through increased translation, thus providing a direct 
link  between  the  HIF/angiogenesis  and  the  mTOR 
paths  to  renal  carcinogenesis.  Because  unregulated 
angiogenesis is a prominent feature of RCC, the inhi-
bition of mTOR is relevant clinically and may inhibit 
angiogenesis  through  a  mechanistic  approach  that 
differs from that of VEGF receptor-targeted agents. In 
addition  to  clear  cell  RCC,  the  spectrum  of  renal 
manifestations  in  TS  also  includes  development  of 
multiple angiomyolipomas, renal cysts, and non-clear 
cell  RCC  (papillary  and  chromophobe  carcinomas). 
Other hereditary RCC syndromes involving non-clear 
cell RCC have also been identified and characterized 
in  terms  of  the  underlying  genetic  lesions;  interest-
ingly,  increased  HIF  expression  and  transcriptional 
activity activation of the mTOR pathway both appear 
to  be  central  to  the  development  of  different  renal 
manifestations  of  disease,  including  benign  (angio-
myolipomas,  renal  cysts,  oncocytomas),  borderline 
(hybrid  oncocytic  tumors),  and  frankly  malignant 
(papillary  and  chromophobe  RCC)  lesions  (10).  Ge-
netic  aberrations  in  TSC1/2  and  Birt-Hogg-Dubè 
(BHD) directly impinge on the activation of the mTOR 
pathway, leading to the development of an array of 
renal  lesions  that  can  be  partially  reversed  by  ra-
pamycin-mediated inhibition of mTOR, both in pre-
clinical models and human patients with TSC; in the 
highly aggressive papillary type 2 RCC observed in 
hereditary  leiomyomatosis  and  renal  cell  cancer 
(HLRCC), fumarate hydratase (FH) deficiency creates 
a pseudohypoxic intracellular environment (9), lead-
ing  to  HIF  accumulation;  from  a  molecular  stand-
point, this situation is similar to that observed in VHL 
mutant RCC cells, where HIF-1 translation and ac-
cumulation  can  be  prevented  by  mTOR  inhibition, 
thereby  rendering  HIF-overexpressing  cells  particu-
larly prone to the growth inhibitory effects of mTOR 
inhibitors,  both  in  vitro  and  in  vivo.  More  recently, 
computational  analysis  of  gene  expression  data  de-
rived from papillary RCC revealed that a transcrip-
tional signature indicative of MYC pathway activation 
is  present  in  high-grade  type  2  papillary  RCC.  The 
MYC signature was associated with amplification of 
chromosome  8q  and  overexpression  of  MYC  that 
maps to chromosome 8q24 and, reflective of the asso-
ciation of an active MYC signature component with 
papillary type 2, the presence of this pathway signa-
ture  component  was  also  associated  with  a  highly 
aggressive clinical behavior and poor overall survival 
(11).  Recent  evidence  indicates  the  existence  of  an 
important  growth-regulatory  crosstalk  between  the 
MYC,  HIF,  and  the  mTOR  pathway:  indeed,  both 
HIF-1  and  HIF-2  may  directly  or  indirectly  control 
MYC  activity,  on  one  hand,  and  tuberin  loss  may 
de-repress MYC protein, on the other, positioning the 
connection  between  these  two  growth  regulators  to 
act  as  a  feed-forward  loop  that  would  amplify  the 
oncogenic  effects  of  decreased  tuberin  or  increased 
MYC expression (12). Overall, both genetic and mo-
lecular data strongly indicate that common avenues 
do  exist  in  renal  carcinogenesis  and  that  HIF  accu-
mulation  and  mTOR  activation  represent  common 
molecular themes across a spectrum of both benign 
renal lesions and different RCC subtypes, including 
both clear cell and non-clear cell forms, and thus con-
stitute  widespread  therapeutic  targets  in  both  spo-
radic and familial RCC. 
Resistance and escape mechanisms 
Understanding  (and  overcoming)  primary 
and/or acquired resistance to both HIF/VEGF- and 
mTOR-targeted agents is perhaps the most important 
issue  to  address,  in  order  to  make  further  clinical 
progresses  in  the  management  of  advanced  RCC. 
While  the  molecular  mechanisms  of  primary  re-
sistance are still elusive, clues to the development of 
acquired resistance in patients that initially respond 
favorably  to  VEGF/VEGF  receptor-targeted  agents 
are starting to emerge (13-14). First, the pathway may 
be incompletely blocked, due to an intrinsically low 
potency of the agent employed as first-line or to an 
adaptive response that leads to increased drug me-
tabolism/extrusion, with consequently reduced effec-
tive drug levels, or to increased signaling through the 
same ligand/receptor pairs that are being targeted (in 
most  cases  VEGF/VEGFRs  and  PDGF/PDGFRs); 
such a resistance mechanism would explain the clini-
cal  finding  of  incomplete  cross-resistance  between 
VEGF/VEGFR-targeted  drugs,  particularly  when 
crossing  over  to  a  second-line  agent  more  potently 
targeting the same pathway. Second, under the selec-
tive  pressure  of  prolonged  treatment  with  an-
ti-angiogenic agents (mostly targeting the VEGF axis), 
RCC may ultimately resume an angiogenic state ei-
ther  by  increasing  HIF-mediated  transcription  of 
VEGF  and  PDGF  or  through  alternative,  non 
HIF-mediated  pro-angiogenic  factors,  such  as  fibro-
blast  growth  factor  (FGF),  interleukin-8  (IL-8),  pla-
cental-derived  growth  factor  (PlGF),  angiopoetins, 
etc.; in these cases, the tumor would still depend on its 
ability to stimulate angiogenesis, thus targeting HIF 
directly or the alternate angiogenic pathway(s) in se- Journal of Cancer 2011, 2 
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quence could still lead to disease control. Third, RCC 
cells  may  adapt  to  an  intrinsically  hypoxic,  an-
ti-angiogenic, microenvironment by activating intra-
cellular  signaling  pathways,  such  as  the  mTOR 
pathway, that would help them coping with a state of 
high metabolic stress, while maintaining their ability 
to grow; the development of resistance through this 
molecular  mechanism  actually  constitutes  the  ra-
tionale  for  sequential  (or  alternating)  VEGF/mTOR 
pathway  targeting,  that  is  becoming  increasingly 
popular in the clinical setting (see below).  
In addition to cancer cell-centered mechanisms 
of  resistance,  a  potentially  important  and  relatively 
unexplored  area  of  research  is  the  contribution  of 
host-derived  microenvironment  to  the  ability  of  tu-
mors  to  adapt  to  prolonged  blockade  of 
VEGF-mediated  angiogenesis  and  escape  from  an-
ti-angiogenic drug mediated growth control (15). For 
example,  increased  host-derived  pericyte  coverage 
and recruitment of bone marrow-derived cell popula-
tions (that are ‘normal’ in nature) may protect tumor 
blood  vessels  and  endorse  restored 
neo-vascularization, even in the presence of continu-
ous VEGF blockade; interestingly, activity of the HIF 
family of transcription factors appears to play a cru-
cial role not only in the biology of the RCC cell itself, 
but also in orchestrating the response of host-derived 
cells to prolonged anti-angiogenesis, thereby consti-
tuting a potential therapeutic target whose direct in-
hibition may simultaneously hit both the cancer cell 
and  the  surrounding  microenvironment.  Finally,  in 
the presence of a hostile, anti-angiogenic, microenvi-
ronment  the  RCC  cell  may  acquire  a  more  motile, 
invasive, phenotype that allows it escaping nutrient 
and oxygen deprivation by metastasizing to different 
organs where they could hijack host-derived protec-
tive mechanisms to create a more favorable environ-
ment (16). Studies conducted in tumors that have be-
come  resistant  to  sunitinib-mediated  an-
ti-angiogenesis, indeed, indicate that resistant tumor 
cells  acquire  a  ‘sarcoma-like’  phenotype,  with  de-
creased  cytokeratin  and  increased  vimentin  expres-
sion (indicative of an epithelial-to-mesenchymal tran-
sition – EMT), invade surrounding tissues, and dis-
play decreased vascular density (17).  
Rationale for sequencing agents with different 
mechanisms of action 
Metabolic adaptation to  stress conditions is an 
important mechanism involved in tumor progression 
and development of resistance mechanisms. A solid 
tumor can outstrip its nutrient and oxygen supply as 
it  grows,  resulting  in  metabolic  stress.  As  a  conse-
quence, tumor cells must undergo a period of meta-
bolic  adaptation  to  survive  this  stress  or  undergo 
apoptosis; angiogenesis and neovascularization is one 
strategy of metabolic adaptation used by tumors to 
relieve this stress, while maintaining their capacity to 
grow indefinitely (18). By blocking angiogenesis for 
prolonged periods of time, as it is usually the case for 
the first-line treatment of metastatic RCC, the tumor is 
put back in a state of metabolic stress, to cope with 
which it must activate alternative relief mechanisms. 
Given  its  strategic  position  in  the  regulation  of  cell 
growth,  metabolism,  and  angiogenesis,  the  mTOR 
pathway is a likely candidate to be a crucial regulator 
of  ‘metabolic  adaptation’  in  situations  in  which  the 
VEGF-based angiogenic switch is pharmacologically 
inhibited. Indeed,  mTOR  senses availability of ami-
noacids,  metabolic  fuel,  and  energy  (essential  for 
protein synthesis, cell growth, proliferation, and sur-
vival) and its activation supports growth and survival 
by increasing cell access to nutrients and  metabolic 
fuels,  through  increased  expression  of  nutrient 
transporters. It is, therefore, reasonable to speculate 
that alternating agents with different modes of action 
would actually turn tumor’s ability to activate either 
neo-angiogenesis  or  mTOR  signaling  to  cope  with 
situations  of  metabolic  stress  to  our  advantage:  in-
deed,  after  prolonged  exposure  to 
VEGF/VEGFR-targeted  agents,  RCC  cells  may  acti-
vate mTOR to cope with metabolic stress and survive; 
if mTOR is blocked at this stage, tumor cells would be 
most sensitive to its action and would go back to a 
neo-angiogenesis driven response to metabolic stress, 
again becoming sensitive to VEGF-targeted strategies. 
Although such hypothesis remains to be tested, both 
experimentally and clinically, solid clinical evidence 
indicates  that  mTOR  inhibitors  are  effective  after 
progression to VEGF/VEGFR-targeted strategies and 
initial reports suggest that rechallenge with a VEGFR 
TKI (even the same agent used as first-line) after an 
mTOR inhibitor may lead to substantial clinical bene-
fit. 
The importance of the ‘host’ 
Another dimension, that is only now starting to 
emerge from the literature, is the complex interplay 
between the cancer cell(s), the host immune system, 
and the molecularly targeted agents that are used for 
treatment. It is relatively well known that the presence 
of a tumor may shape host immune response by cre-
ating  an  immunosuppressive  environment;  in  the 
specific  case  of  RCC,  which  is  characterized  by 
prominent  activation  of  the  HIF/VEGF  axis,  VEGF 
itself and/or other cytokines produced by tumor cells 
exert  profound  immunosuppressive  effects  by  im-
pairing dendritic cell maturation from myeloid pro- Journal of Cancer 2011, 2 
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genitors,  increasing  Treg-mediated  suppression  of 
T-cell responses, and shifting the balance towards a 
Th2 type of response with secondary production of 
IL-10, IL-4, and IL-6. Not only tumors, including RCC, 
may effectively suppress tumor-specific immune re-
sponses,  but  they  can  also  hijack  host-derived  cell 
populations,  turning  them  into  powerful  allies  that 
help creating a pro-angiogenic, tumor-promoting mi-
croenvironment (19): indeed, tumor-infiltrating mac-
rophages, neutrophils, dendritic cells (DCs), and nat-
ural killer cells may shift from the production of an-
ti-angiogenic/tumor  suppressing  cytokines,  such  as 
IFN- and IL-12, to the secretion of VEGF, PlGF, FGF, 
PDGF,  IL-8,  matrix  metalloproteases  (MMPs),  cy-
clooxygenase-2  (Cox-2),  and  arginase;  moreover,  in 
the tumor microenvironment myeloid progenitor cells 
may be forced to  differentiate into myeloid-derived 
stromal  cells  (MDSCs),  that  potently  support  tu-
mor-driven  vasculogenesis  and  help  protecting  tu-
mor-associated  neo-vessels  from  anti-angiogenic 
therapeutic attack.  
The  immune-modulatory  effects  of  therapeutic 
agents (mostly VEGF/VEGFR and mTOR inhibitors) 
commonly used to treat RCC are only beginning to 
surface  (20).  For  example,  two  commonly  used  an-
ti-angiogenic  multi-kinase  inhibitors,  such  as  soraf-
enib  and  sunitinib,  clearly  differ  in  their  ability  to, 
directly  or  indirectly,  influence  immune  response: 
indeed, sorafenib appears to impair, while sunitinib 
stimulates,  terminal  DC  maturation  and  ability  to 
co-stimulate  T-cell  responses;  sunitinib,  but  not  so-
rafenib, inhibits MDSC immune-suppressive activity, 
reduces  both  MDSC  and  Treg  circulating  numbers, 
and corrects Th2 bias. It would be even more inter-
esting to understand the immunomodulatory effects 
of rapamycin derivatives, such as temsirolimus and 
everolimus, in the specific context of RCC treatment, 
considering  their  well-established  alternative  use  as 
immunosuppressants in organ transplantation. 
Summary and conclusions 
In the past ten years we have made exceptional 
progresses in the understanding of RCC biology, par-
ticularly by recognizing the crucial pathogenetic role 
of activation of the HIF/VEGF and mTOR pathways. 
This has resulted in the successful clinical develop-
ment  of  anti-angiogenic  and  mTOR-targeted  drugs, 
which have profoundly impacted on the natural his-
tory of the disease and have improved the duration 
and  quality  of  RCC  patient  lives.  However,  further 
improvements are still greatly needed, particularly in 
the quest for ‘curative’ treatments, currently lacking 
in the setting of advanced RCC. As highlighted above, 
unraveling the complex mechanisms by which RCC 
shapes host microenvironment and immune response 
and therapeutic treatments, in turn, shape both cancer 
cell biology and tumor-host interactions may hold the 
key to future advances in such a complex and chal-
lenging disease. 
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